COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD OF CARE FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AS 4TH OR LATER LINE TREATMENT IN SWEDEN

被引：0
|
作者：
Eklund, O. [1 ]
Kanje, V. Hedlof [1 ]
Doble, B. [2 ]
Cervin, K. [1 ]
机构：
[1] Gilead Sci AB, Stockholm, Sweden
[2] Kite Pharma, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE536
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD OF CARE FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN SWEDEN, NORWAY, FINLAND, AND DENMARK
    Karampampa, K.
    Stene, E.
    Axelsen, F.
    Lyngaa, R.
    Vadgama, S.
    Jerkeman, M.
    Wilen-Koort, A.
    Wallace, K.
    VALUE IN HEALTH, 2020, 23 : S687 - S687
  • [2] Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States
    Oluwole, Olalekan O.
    Ray, Markqayne D.
    Rosettie, Katherine L.
    Ball, Graeme
    Jacob, Jorge
    Bilir, Pinar
    Patel, Anik R.
    Jacobson, Caron A.
    BLOOD, 2022, 140 : 10822 - 10824
  • [3] Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States
    Oluwole, Olalekan O.
    Ray, Markqayne D.
    Rosettie, Katherine L.
    Ball, Graeme
    Jacob, Jorge
    Bilir, S. Pinar
    Patel, Anik R.
    Jacobson, Caron A.
    VALUE IN HEALTH, 2024, 27 (08) : 1030 - 1038
  • [4] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [5] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
    Topp, Max
    Van Meerten, Tom
    Houot, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duhrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose'
    BLOOD, 2019, 134
  • [6] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J.
    Sorensen, Sonja
    Dorman, Emily
    BLOOD, 2021, 138
  • [7] Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US
    Oluwole, Olalekan O.
    Ray, Markqayne D.
    Zur, Richard
    Little, Aurelia
    Ferrufino, Cheryl
    Doble, Brett
    Patel, Anik R.
    Bilir, Pinar
    BLOOD, 2023, 142
  • [8] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [9] A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
    Jacobson, Caron A.
    Falvey, Caroline
    Bouvier, Riemke
    Hogan, Sarah
    Kendricken, Elizabeth
    Jones, Julia
    Grimm, Elizabeth
    Redd, Robert A.
    Lee, Eudocia Q.
    Castro, Luis Gonzalez
    Chukwueke, Ugonma
    Figueroa, Jose McFaline
    Kim, Austin, I
    Torres, Alexandra
    Ramsdell, Linda
    Kean, Leslie S.
    Gerdemann, Ulrike
    Albanese, Alexandre
    Keskula, Paula
    Meredith, David
    Sholl, Lynette
    Poddar, Soumya
    Davis, Madison
    Mao, Daquin
    Filosto, Simone
    Mattie, Mike
    Armand, Philippe
    Nayak, Lakshmi
    BLOOD, 2022, 140 : 1060 - 1061
  • [10] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
    Topp, M. S.
    van Meerten, T.
    Wermke, M.
    Lugtenburg, P. J.
    Minnema, M. C.
    Song, K. W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
12345